🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Chinese Pulmonary Vascular Disease Research Group clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Chinese Pulmonary Vascular Disease Research Group as lead sponsor. Synced 26 Sep 2026
5Current trials
5Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 5 current clinical trials in our China register. 5 are recruiting patients now. All registered phases are Observational. The most-studied condition is Pulmonary Hypertension.

ClinicalTrials.gov trials by status

  • Recruiting5100%

Trials by phase

  • Observational5100%
01

Clinical trials sponsored by Chinese Pulmonary Vascular Disease Research Group

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
NCT05566002 · ClinicalTrials.gov ↗ · Pulmonary Hypertension, Pulmonary Arterial Hypertension
Observational Recruiting 2022-06 China
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
NCT05388682 · ClinicalTrials.gov ↗ · Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
Observational Recruiting 2014-01 China
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
NCT04206852 · ClinicalTrials.gov ↗ · Chronic Thromboembolic Pulmonary Hypertension
Observational Recruiting 2018-05 China
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
NCT02061787 · ClinicalTrials.gov ↗ · Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)
Observational Recruiting 2010-09 China
CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
NCT06135909 · ClinicalTrials.gov ↗ · Pulmonary Hypertension
Observational Recruiting 2020-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Chinese Pulmonary Vascular Disease Research Group trials

7 conditions
Pulmonary Hypertension3Chronic Thromboembolic Pulmonary Hypertension2Pulmonary Arterial Hypertension1Takayasu Arteritis With Pulmonary Artery Involvement1Percutaneous Transluminal Pulmonary Angioplasty1PAH Targeted Medication1Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China55

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Pulmonary Hypertension

SponsorTrials
Pulmovant3
Insmed Incorporated2
35Pharma1
Tenax Therapeutics1
Tempus AI1
Eko Devices1

Sponsors with the most current trials registered for this condition.

05

Questions about Chinese Pulmonary Vascular Disease Research Group trials

How many clinical trials does Chinese Pulmonary Vascular Disease Research Group sponsor?

Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chinese Pulmonary Vascular Disease Research Group trials recruiting?

Yes. 5 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.